secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001367644-24-000118
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent settles Janssen COVID vaccine manufacturing dispute; receives $50M
---------------------------------------------------------------------------

- Janssen will pay Emergent $50M by July 31, 2024 under settlement agreement.
- Settlement resolves all claims and arbitration related to MSA for Ad26.COV2-S vaccine.
- Parties exchange broad releases covering affiliates, officers, and directors.
- Ends previously disclosed arbitration between Emergent and Janssen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000118/0001367644-24-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000118/ebs-20240703.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer